The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial

IMPORTANCE: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Sledge, George W., Toi, Masakazu, Neven, Patrick, Sohn, Joohyuk, Inoue, Kenichi, Pivot, Xavier, Burdaeva, Olga, Okera, Meena, Masuda, Norikazu, Kaufman, Peter A., Koh, Han, Grischke, Eva-Maria, Conte, PierFranco, Lu, Yi, Barriga, Susana, Hurt, Karla, Frenzel, Martin, Johnston, Stephen, Llombart-Cussac, Antonio
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2019
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777264/
https://ncbi.nlm.nih.gov/pubmed/31563959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.4782
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky